A Monte Carlo study of cellular S-factors for 1 keV to 1 MeV electrons

A systematic study of cellular S-factors and absorbed fractions for monoenergetic electrons of initial energy from 1 keV to 1 MeV is presented. The calculations are based on our in-house Monte Carlo codes which have been developed to simulate electron transport up to a few MeV using both event-by-event and condensed-history techniques. An extensive comparison with the MIRD tabulations is presented for spherical volumes of 1-10 microm radius and various source-to-target combinations relevant to the intracellular localization of the emitted electrons. When the primary electron range is comparable to the sphere radius, we find significantly higher values from the MIRD, while with increasing electron energy the escape of delta-rays leads gradually to the opposite effect. The largest differences with the MIRD are found for geometries where the target region is at some distance from the source region (e.g. surface-to-nucleus or cytoplasm-to-nucleus). The sensitivity of the results to different transport approximations is examined. The grouping of inelastic collisions is found adequate as long as delta-rays are explicitly simulated, while the inclusion of straggling for soft collisions has a negligible effect.

[1]  D. Le Guludec,et al.  Comparison of cellular and conventional dosimetry in assessing self-dose and cross-dose delivered to the cell nucleus by electron emissions of 99mTC, 123I, 111In, 67Ga and 201Tl , 1998, European Journal of Nuclear Medicine.

[2]  Anirban Pathak,et al.  A Monte Carlo study of energy deposition at the sub-cellular level for application to targeted radionuclide therapy with low-energy electron emitters , 2007 .

[3]  J. Sempau,et al.  PENELOPE-2006: A Code System for Monte Carlo Simulation of Electron and Photon Transport , 2009 .

[4]  Geoff Delaney,et al.  The role of radiotherapy in cancer treatment , 2005, Cancer.

[5]  M. Bardiès,et al.  A simplified approach to alpha dosimetry for small spheres labelled on the surface. , 1990, Physics in medicine and biology.

[6]  G. Ferro-Flores,et al.  Monte Carlo microdosimetry of 188Re- and 131I-labelled anti-CD20 , 2006, Physics in medicine and biology.

[7]  Thomas F. Budinger,et al.  MIRD primer for absorbed dose calculations , 1988 .

[8]  Christophe Champion,et al.  CELLDOSE: A Monte Carlo Code to Assess Electron Dose Distribution—S Values for 131I in Spheres of Various Sizes , 2007, Journal of Nuclear Medicine.

[9]  T. Wheldon,et al.  The radiobiology of targeted radiotherapy. , 1990, International journal of radiation biology.

[10]  R. K. Bull,et al.  Stopping powers for electrons and positrons: ICRU Report 37; 271 pp.; 24 figures; U.S. $24.00. , 1986 .

[11]  D. Oscier,et al.  Divergence from the germ-line sequence in unmutated chronic lymphocytic leukemia is due to somatic mutation rather than polymorphisms. , 2003, Blood.

[12]  A. Nahum Microdosimetry and radiocurability: modelling targeted therapy with -emitters , 1996 .

[13]  Wei Bo Li,et al.  Track Structures and Dose Distributions from Decays of 131I and 125I in and around Water Spheres Simulating Micrometastases of Differentiated Thyroid Cancer , 2001, Radiation research.

[14]  N Lanconelli,et al.  Differences among Monte Carlo codes in the calculations of voxel S values for radionuclide targeted therapy and analysis of their impact on absorbed dose evaluations. , 2009, Medical physics.

[15]  A. Pathak,et al.  Subcellular S-factors for low-energy electrons: A comparison of Monte Carlo simulations and continuous-slowing-down calculations , 2008, International journal of radiation biology.

[16]  P. Hadjidoukas,et al.  The effects of energy-loss straggling and elastic scattering models on Monte Carlo calculations of dose distribution functions for 10 keV to 1 MeV incident electrons in water , 2009 .

[17]  B. Fallone,et al.  Monte Carlo investigation of single cell beta dosimetry for intraperitoneal radionuclide therapy. , 2004, Physics in medicine and biology.

[18]  J. Baró,et al.  PENELOPE: An algorithm for Monte Carlo simulation of the penetration and energy loss of electrons and positrons in matter , 1995 .

[19]  G. Barendsen,et al.  Absorbed dose distribution of the auger emitters 67GA and 125I and the beta-emitters 67CU, 90Y, 131I, and 186RE as a function of tumor size, uptake, and intracellular distribution. , 1996, International journal of radiation oncology, biology, physics.

[20]  Kostas Kostarelos,et al.  A Monte Carlo track structure code for electrons (~10 eV-10 keV) and protons (~0.3-10 MeV) in water: partitioning of energy and collision events , 2000 .

[21]  Franz Buchegger,et al.  Auger radiation targeted into DNA: a therapy perspective , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  I. Gardin,et al.  Modelling of the relationship between cell dimensions and mean electron dose delivered to the cell nucleus: application to five radionuclides used in nuclear medicine. , 1995, Physics in medicine and biology.

[23]  I. Kawrakow Accurate condensed history Monte Carlo simulation of electron transport. I. EGSnrc, the new EGS4 version. , 2000, Medical physics.

[24]  H. Paretzke,et al.  Comparison of Energy Deposition in Small Cylindrical Volumes by Electrons Generated by Monte Carlo Track Structure Codes for Gaseous and Liquid Water , 1994 .

[25]  J. Fernández-Varea,et al.  Comparison of Monte Carlo calculated electron slowing-down spectra generated by 60Co gamma-rays, electrons, protons and light ions. , 2002, Physics in medicine and biology.

[26]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. J. Strom,et al.  Microdosimetric properties of ionizing electrons in water: a test of the PENELOPE code system. , 2002, Physics in medicine and biology.

[28]  J. Fernández-Varea,et al.  A relativistic optical-data model for inelastic scattering of electrons and positrons in condensed matter , 2005 .

[29]  Calculations of Electron Single Event Distributions for Use in Internal Beta Microdosimetry , 1994 .

[30]  M G Stabin,et al.  Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  J L Humm,et al.  Dosimetric aspects of radiolabeled antibodies for tumor therapy. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  G. Sgouros Alpha-particles for targeted therapy. , 2008, Advanced drug delivery reviews.

[33]  L. Gordon,et al.  Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. , 2004, Blood.

[34]  A. Kassis The MIRD approach: remembering the limitations. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  S. Adelstein,et al.  Radiobiologic principles in radionuclide therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  C. Tung,et al.  Low-energy electron interactions with liquid water and energy depositions in nanometric volumes , 2007 .

[37]  R. Böhm,et al.  Monte Carlo Calculations of Energy Deposition in DNA for Auger Emitters , 2000 .

[38]  David W. O. Rogers,et al.  A Comparison of EGS and ETRAN , 1988 .

[39]  H. Lundqvist,et al.  Radiation doses to the cell nucleus in single cells and cells in micrometastases in targeted therapy with (131)I labeled ligands or antibodies. , 2000, International journal of radiation oncology, biology, physics.

[40]  M A Bernal,et al.  An investigation on the capabilities of the PENELOPE MC code in nanodosimetry. , 2009, Medical physics.

[41]  M. Stabin,et al.  Nuclear medicine dosimetry , 2006, Physics in medicine and biology.

[42]  Richard L Wahl,et al.  131I-tositumomab therapy as initial treatment for follicular lymphoma. , 2005, The New England journal of medicine.

[43]  I. Bernstein,et al.  Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas , 1995, The Lancet.

[44]  R. Howell,et al.  Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors. , 1989, Medical physics.

[45]  Comparison of Microdosimetric Simulations Using PENELOPE and PITS for a 25 keV Electron Microbeam in Water , 2002, Radiation research.

[46]  T. Wheldon,et al.  Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  P. Hadjidoukas,et al.  A Monte Carlo study of absorbed dose distributions in both the vapor and liquid phases of water by intermediate energy electrons based on different condensed-history transport schemes , 2008, Physics in medicine and biology.

[48]  S. Goddu,et al.  Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  B Aubert,et al.  Validation of the EGS usercode DOSE3D for internal beta dose calculation at the cellular and tissue levels. , 2003, Physics in medicine and biology.

[50]  M. J. Berger ESTAR, PSTAR, and ASTAR: Computer programs for calculating stopping-power and range tables for electrons, protons, and helium ions , 1992 .

[51]  M Bardiès,et al.  Dosimetry and microdosimetry of targeted radiotherapy. , 2000, Current pharmaceutical design.

[52]  D. Georg,et al.  Targeted radionuclide therapy: theoretical study of the relationship between tumour control probability and tumour radius for a 32P/33P radionuclide cocktail , 2008, Physics in medicine and biology.

[53]  S. Goddu,et al.  Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  Kostas Kostarelos,et al.  Single-cell dosimetry for radioimmunotherapy of B-cell lymphoma patients with special reference to leukemic spread. , 2007, Cancer biotherapy & radiopharmaceuticals.

[55]  G. Sgouros Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  R. Stewart,et al.  Monte Carlo simulation of DNA damage induction by x-rays and selected radioisotopes , 2008, Physics in medicine and biology.

[57]  C. Punt,et al.  Clinical applications of newer radionuclide therapies. , 2006, European journal of cancer.

[58]  C. Divgi,et al.  Current status of therapy of solid tumors. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[59]  A. Barrett,et al.  The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[60]  A. Cole Absorption of 20-eV to 50,000-eV electron beams in air and plastic. , 1969, Radiation research.

[61]  G T Chen,et al.  Microdosimetric concepts in radioimmunotherapy. , 1993, Medical physics.

[62]  Yong-ki Kim,et al.  Extension of the binary-encounter-dipole model to relativistic incident electrons , 2000 .

[63]  S. Chauvie,et al.  Geant4 Physics Processes for Microdosimetry Simulation: Design Foundation and Implementation of the First Set of Models , 2007, IEEE Transactions on Nuclear Science.

[64]  O. Press,et al.  Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience , 2000, Annals of Hematology.

[65]  Herman Feshbach,et al.  The Coulomb Scattering of Relativistic Electrons by Nuclei , 1948 .

[66]  D. Rao,et al.  Electron Dosimetry for Radioimmunotherapy: Optimal Electron Energy , 1985 .

[67]  S. Strand,et al.  Internal microdosimetry for single cells in radioimmunotherapy of B-cell lymphoma. , 2005, Cancer biotherapy & radiopharmaceuticals.

[68]  C. Tung,et al.  Calculations of cellular microdosimetry parameters for alpha particles and electrons. , 2004, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[69]  C. Zanelli,et al.  Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy. , 1984, The International journal of applied radiation and isotopes.

[70]  J A Parker,et al.  Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2001, Critical reviews in oncology/hematology.

[71]  P. Hadjidoukas,et al.  Electron ionization cross-section calculations for liquid water at high impact energies , 2008 .

[72]  R. Howell The MIRD Schema: from organ to cellular dimensions. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[73]  M. Brechbiel,et al.  Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.